Grants and Contributions:
Title:
In vivo characterization of a novel cancer immunotherapeutic antibody
Agreement Number:
926712
Agreement Value:
$82,000.00
Agreement Date:
Apr 1, 2019 - Jan 31, 2020
Description:
The project will involve characterization of lead antibody product in in vivo cancer models to establish a robust efficacy profile.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
North Hatley, British Columbia, CA V7L 4B4
Reference Number:
172-2019-2020-Q1-926712
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
837332592
Recipient Type:
For-profit organization
Recipient's Legal Name:
ME Therapeutics Inc.
Federal Riding Name:
North Vancouver
Federal Riding Number:
59021
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710